Flu Panel: Specimen Collection and Antiviral Treatment
For suspected influenza, obtain a nasopharyngeal swab for rapid multiplex respiratory viral PCR testing and initiate oseltamivir 75 mg twice daily for 5 days if the patient presents within 48 hours of symptom onset, is hospitalized, has severe/progressive illness, or has high-risk features—regardless of test results if clinical suspicion is high.
Specimen Collection Technique
Nasopharyngeal swabs are the optimal specimen type for respiratory viral panel testing 1. The most recent evidence supports a simplified collection approach:
- Insert the swab into the nostril parallel to the palate until resistance is met at the nasopharynx
- One slow rotation is sufficient and provides equivalent sample quality to five rotations while causing significantly less patient discomfort 2
- Flocked swabs outperform non-flocked swabs for viral detection 3
- Mid-turbinate nasal swabs are acceptable alternatives to nasopharyngeal swabs and are less invasive 3
Special Circumstances:
- Hospitalized patients with respiratory failure on mechanical ventilation: Collect endotracheal aspirate or bronchoalveolar lavage fluid, especially if upper respiratory specimens are negative 3
- Immunocompromised patients: Use multiplex RT-PCR panels targeting multiple respiratory pathogens 3
Diagnostic Testing Strategy
Use rapid molecular assays (RT-PCR or nucleic acid amplification tests) over rapid antigen tests 3. The hierarchy of testing is:
- Outpatients: Rapid molecular assays preferred; rapid antigen tests acceptable 3
- Hospitalized patients: RT-PCR or molecular assays mandatory; do not use rapid antigen tests unless molecular testing unavailable 3
- Multiplex respiratory panels should be considered for patients with cough or shortness of breath to detect RSV, influenza, parainfluenza, adenovirus, rhinovirus, and metapneumovirus 4
Antiviral Treatment Decision Algorithm
Immediate Treatment Indicated (Start Within 48 Hours of Symptom Onset):
Treat empirically without waiting for test results if:
- Any hospitalized patient with suspected influenza 3, 4
- Outpatients with severe or progressive illness 3
- High-risk patients including:
Standard Treatment Regimen:
Oseltamivir 75 mg orally every 12 hours for 5 days 4, 6
Dose adjustments:
- Reduce to 75 mg once daily if creatinine clearance <30 mL/min 6
Alternative Agents:
- Zanamivir: Active against influenza A and B 4, 1
- Peramivir (IV): For patients unable to absorb oral oseltamivir or tolerate oral/inhaled medications 4
- Baloxavir: WHO conditionally recommends for high-risk patients with non-severe illness 7; however, limited data in immunocompromised patients and resistance concerns limit routine use 4
Critical Timing Considerations
The 48-hour window is a guideline, not an absolute cutoff:
- Clinical benefit is highest when treatment starts within 48 hours 4, 6
- Hospitalized patients who are severely ill or immunocompromised may benefit from treatment initiated >48 hours after symptom onset 4, 6
- Consider treatment until symptom resolution in immunocompromised patients (controversial, but some centers use 10-day courses) 4
Special Populations:
Immunocompromised patients:
- Some centers use higher doses (oseltamivir 150 mg twice daily) with mixed results 4
- Longer treatment courses (≥10 days) can be considered 4
Patients unable to mount fever response (elderly, immunocompromised):
- May still be eligible for treatment despite lack of documented fever 6
Common Pitfalls to Avoid
- Do not delay empirical antiviral treatment in high-risk or hospitalized patients while awaiting test results 4, 6
- Do not use rapid antigen tests in hospitalized patients when molecular assays are available; if used, confirm negative results with RT-PCR 3
- Do not collect throat swabs alone—nasopharyngeal or mid-turbinate nasal swabs have superior sensitivity 3
- Do not withhold treatment beyond 48 hours in severely ill or immunocompromised hospitalized patients 4, 6
- Do not routinely add antibiotics for uncomplicated influenza without pneumonia 6